The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 427.50
Bid: 420.00
Ask: 435.00
Change: -12.50 (-2.84%)
Spread: 15.00 (3.571%)
Open: 440.00
High: 435.00
Low: 427.50
Prev. Close: 440.00
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

China Licence received

12 May 2011 08:00

RNS Number : 4596G
Tristel PLC
12 May 2011
 



Tristel plc

("Tristel" or "the Company")

AIM: TSTL

 

Licence to sell Stella decontamination system received in China

 

Tristel plc, the manufacturer of infection control, contamination control and hygiene products, announces that it has received the administrative licence that will enable the use of its Stella decontamination system in China.

 

Stella is a sophisticated micro-processor controlled tray in which medical instruments are immersed in Tristel's chlorine dioxide disinfectant. Hospitals can employ Stella at a fraction of the capital and running cost of the endoscope washers that are widely used as the only alternative to the age-old practice of placing instruments in a sink or simple plastic container.

 

Stella is particularly relevant to hospital departments such as urology, gynaecology, respiratory, cardiology and GI physiology. It deliberately cannot be used with the large flexible endoscopic instruments that are the focus of most of Tristel's competitors.

 

Tristel received regulatory approval for Stella last Autumn and the receipt of the licence enables its use by hospitals. The Company's China subsidiary, Shanghai Stella Medical Equipment Co. Ltd., has already appointed six distributors for the Stella system. These distributors purchased 30 Stella units between June and December 2010 for training and evaluation purposes. The Company has established its own sales force to sell directly in the Shanghai metropolitan area.

 

Outside of China, Tristel has sold 63 Stella units in the United Kingdom, Belgium, Spain, Ireland, Italy, Dubai, New Zealand and Germany. In a clinical study recently concluded Stella has been subjected to a randomised single-blind comparison with the world's leading brand of instrument disinfectant used in one of the most widely used endoscope washers. Stella's efficacy has been shown to be the equivalent of the process to which it was compared, but it produced vast savings in cost and process time. The study is anticipated to be published later this year.

 

Paul Swinney, Chief Executive of Tristel, said: "We have been eagerly awaiting receipt of this licence for many months because Stella sales in China had been forecast to be a major contributor to our top-line growth this year. Our team in Shanghai will now make every effort to close as much business as possible although our year end is approaching fast. We are confident that the market in China will play an important part in next year's business plan and to this end I am pleased to report that our Tristel Jet product for hard surface disinfection has also been approved by the regulatory body. We have now entered the administrative licence process for this product. Our Wipes System is also in the process of being presented for regulatory approval."

 

Tristel plc

Paul Swinney, Chief Executive

Tel: 01638 721 500

finnCap

Geoff Nash / Charlotte Stranner (Corporate Finance)

Simon Starr (broking)

Tel: 020 7600 1658

Walbrook PR

Tel: 020 7933 8780

Paul McManus (Media Relations)

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

Paul Cornelius (Investor Relations)

Mob: 07866 384 707

paul.cornelius@walbrookir.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFDSMEFFSEII
Date   Source Headline
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM
12th Dec 20227:00 amRNSAGM Statement
2nd Nov 20221:50 pmRNSHolding(s) in Company
25th Oct 20227:00 amRNSAudited Preliminary Results
6th Oct 20229:15 amRNSIssue of Equity
4th Oct 202212:00 pmRNSAppointment of new Company Secretary
4th Oct 20227:00 amRNSNotice of Results & Investor Presentation
29th Sep 20221:00 pmRNSNorth America update
30th Aug 20227:00 amRNSHolding(s) in Company
22nd Jul 20221:05 pmRNSDirector/PDMR Shareholding
21st Jul 202210:15 amRNSHolding(s) in Company
18th Jul 20224:41 pmRNSSecond Price Monitoring Extn
18th Jul 20224:35 pmRNSPrice Monitoring Extension
18th Jul 20227:00 amRNSTrading update and special dividend
30th Jun 20227:00 amRNSDe Novo FDA submission for Tristel Duo ULT
20th Jun 202210:00 amRNSShareholder Open Day & Notice of Trading update
7th Jun 20221:15 pmRNSHolding(s) in Company
4th May 20227:00 amRNSInvestor Presentation
3rd May 202212:30 pmRNSHolding(s) in Company
14th Apr 202212:00 pmRNSIssue of Equity
6th Apr 202212:10 pmRNSDirector/PDMR Shareholding
5th Apr 20222:45 pmRNSDirector/PDMR Shareholding
29th Mar 20223:40 pmRNSDirector/PDMR Shareholding
23rd Feb 20224:45 pmRNSInterim dividend confirmation
22nd Feb 202211:30 amRNSDirector/PDMR Shareholding
21st Feb 20224:40 pmRNSSecond Price Monitoring Extn
21st Feb 20224:35 pmRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSHalf-year Report
17th Feb 20223:00 pmRNSIssue of Equity
1st Feb 20227:00 amRNSConfirmation of Interim Results
13th Dec 20215:13 pmRNSResult of AGM
13th Dec 20217:00 amRNSAGM Statement and notice of results
27th Oct 20217:00 amRNSDirector/PDMR Shareholding
21st Oct 20214:39 pmRNSDirector/PDMR Shareholding
19th Oct 20215:35 pmRNSHolding(s) in Company
18th Oct 20213:50 pmRNSIssue of Equity
18th Oct 202111:59 amRNSDirector/PDMR Shareholding
18th Oct 20217:00 amRNSFinal Results
12th Oct 20215:58 pmRNSHolding(s) in Company
22nd Sep 20217:00 amRNSNotice of Results
23rd Aug 20217:00 amRNSIssue of Equity
10th Aug 20217:00 amRNSIssue of Equity
29th Jul 20216:29 pmRNSTR1: Notification of Major Holdings
21st Jul 20217:00 amRNSTrading update
9th Jul 20211:21 pmRNSIssue of Equity
24th Jun 20217:00 amRNSRegulatory approval for EPA, Canada & South Korea
8th Jun 20217:00 amRNSIssue of Equity
13th May 20213:30 pmRNSIssue of Equity
26th Apr 20213:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.